A simple, sensitive, precise and accurate method for simultaneous estimation of metformin and sitagliptin from human plasma was developed and validated. Samples extracted from plasma using acetonitrile were separated on an SCX column and estimated using API 4000 Mass Spectrometer in the positive atmospheric pressure ionization mode (Turboionspray) by following multiple reaction monitoring transitions for both parent and daughter ions. A linear calibration plot was achieved for both the analytes in the concentration ranges of 10-2,206 ng/mL (for metformin) and 3 -800.5 ng/mL (for sitagliptin) prepared in K 2 EDTA pooled plasma. Mean recovery for metformin was 92% and for sitagliptin was 104.5%. It is a fully validated method and successfully applied for estimation of these drug molecules during biostudies.
Introduction
Metformin hydrochloride (N, N-dimethylimidocarbonimidic diamide), an oral anti-diabetic drug is used as a first-line choice for the treatment of type 2 diabetes, particularly in overweight or obese people and those with normal kidney function. Metformin improves hyperglycemia, primarily through its suppressive action on hepatic gluconeogenesis and also by increasing glucose transport across the cell membrane in skeletal muscle (1 -3) . Sitagliptin phosphate f1,2,4-triazolo [4,3-a] pyrazine,7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluoro phenyl) butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl), phosphateg is an oral anti-diabetic drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Sitagliptin competitively inhibits DPP-4, an enzyme involved in the breakdown of incretins such as glucagon-like particle-1 (GLP-1), which potentiate insulin secretion in vivo. Inhibition of DPP-4 reduces the breakdown of GLP-1 and increases insulin secretion; this suppresses the release of glucagon from the pancreas and drives down blood sugar levels (4 -6). However, this drug is not official in any pharmacopoeia. The need for effective management of diabetes is of utmost importance due to a continuous increase in the number of incidence of diabetes worldwide. Recently, the combination of two drugs, metformin and sitagliptin, has been recommended in the treatment of diabetes mellitus to improve glycemic control (7) . This combination proved to be effective in controlling the metabolic syndrome and resulted in significant weight loss, reversal of insulin resistance, islet and adipocyte hypertrophy and hepatic steatosis.
It is traditionally difficult to measure a highly polar molecule like metformin. Several analytical methods based on UV (8 -10), spectroflourimetry (11) , RP-HPLC (12 -14) , HPTLC (15, 16) and LC-MS-MS (17 -19) were reported for the determination of either metformin or sitagliptin. However, there is hardly any sensitive, validated method available for simultaneous estimation of these two drugs in biological specimen (16, 19, 20) . A new sensitive and precise method for simultaneous estimation of these two drugs in human plasma is reported here. This validated method (as per the FDA validation procedure) is also used for quantitation of these drugs for pharmacokinetic studies during biostudies (21) .
Experimental
Reagents Metformin (USP) was purchased from LGC Promochem, whereas deuterated metformin, used as an internal standard (IS), was from Vivan Life Sciences. Similarly, sitagliptin and deuterated sitagliptin (IS) were purchased from Vivan Life Sciences and Clearsynth, respectively. HPLC grade acetonitrile were obtained from E Merck (India). All other chemicals of the highest purity grade were locally purchased. Milli-Q water (Millipore, USA) was used throughout the procedure.
Blood was collected in-house from healthy volunteers in the vacutainers containing K 2 EDTA as an anti coagulant. Plasma was separated by centrifuging at 3,000 rpm for 10 min at 48C.
Preparation of standard samples
Stock solutions (1 mg/mL) of metformin and sitagliptin were prepared in Milli-Q water. Concentration was then corrected using the potency and actual amount weighed. Working solutions of metformin (501.5 -110,740 ng/mL) were prepared by a serial dilution of the stock solution by Milli-Q water.
Similarly, stock solution of sitagliptin was diluted in the concentration range of 152 -83,830 ng/mL using Milli-Q water to prepare working solutions.
For (ISs, stock solution (1 mg/mL) of deuterated metformin (Metformin D6) or deuterated sitagliptin (Sitagliptin D4) was prepared in Milli-Q water and corrected final concentration is obtained using the potency and amount weighed. Working solution (10 mg/mL) was then prepared from this stock solution by a serial dilution using methanol : water (1 : 1, v/v) as a diluent.
All diluted solutions were stored in refrigerator at 2-88C until analysis.
Preparation of calibration standards
To prepare calibration curve standards, 960 mL of K 2 EDTA pooled plasma was spiked with 20 mL of respective working standard of each of metformin and sitagliptin to obtain a concentration range of 10 -2,215 ng/mL for metformin and 3 -806 ng/mL for sitagliptin. All samples were stored at 2708C until use.
Preparation of quality control samples
A concentration range of 10-1,716 ng/mL for metformin and 3-620 ng/mL for sitagliptin was prepared by spiking 20 mL of each working standard of metformin and sitagliptin into 960 mL of K 2 EDTA pooled plasma and stored at 2708C.
Bioequivalence study A study has been conducted to prove the bioequivalence of the test product (a combination product of metformin and sitagliptin) with the reference marketed product as per the preapproved protocol and other documents by the Independent Ethics Committee (I.E.C. Consultants, Bangalore, India; EC Regn. No. ECR/60/Indt/KA/2013; validity: 3 years). Based on the inclusion and exclusion criteria mentioned in the protocol, 36 healthy human subjects who voluntarily provided the informed consent had been recruited for this study. The study was conducted as per the protocol, Good Clinical Practice (GCP) and the applicable principles of Good Laboratory Practices (GLPs).
Methods

Sample extraction
After thawing at room temperature (258C), each sample was vortexed to ensure complete mixing of the contents. About 50 mL of IS (mixture of Metformin D6 and Sitagliptin D4 containing 500 ng/mL each) was then added to 100 mL of all samples, except blank, vortexed and then 1,000 mL of acetonitrile. All samples were kept in vibramax for 10 min at 2,500 rpm. This denaturation of protein during sample preparation helps in the uniform recovery. The samples were then centrifuged at 11,000 rpm for 5 min at 48C. About 500 mL of supernatant was transferred into a new labeled RIA vial and 500 mL of Milli-Q water was added. After vortexing, the samples were transferred to labeled HPLC vials and loaded into an autosampler. About 15 mL of samples was injected to LC-MS-MS for analysis. 
Chromatography
Results
Matrix factor
Six replicates of aqueous standard containing analytes at low QC sample (LQC; within 3Â the LLOQ) concentration and the intended IS concentration were injected. Similarly, eight blank matrix ( plasma from different lots) were spiked either with LQC concentration of analytes (both metformin and sitagliptin) and intended concentration of IS (Metformin D6 and Sitagliptin D4) or high QC (HQC; one near the upper boundary of the standard curve) concentration of analytes and intended concentration of IS. Individual analyte area response and IS area response of each post-extracted sample were compared with the mean analyte area response and mean IS area response of the aqueous standard, respectively. % CV for matrix factor for both metformin and sitgliptin was well within the acceptance range ( 15% ;  Tables I and II) . The average percent matrix factors were 99 + 1 (for metformin) and 101 + 2 (for sitagliptin).
Specificity and selectivity
For selectivity analysis, eight different lots of plasma including one hemolyzed and one lipemic lots were spiked with analytes and IS. Interferences at the retention times of analytes and IS were evaluated by comparing peak area response with that of blank plasma. The signal-to-noise ratio for all lots was more than 5.0, indicating that the method is selective for both metformin and sitagliptin. Retention times for both metformin and Metformin D6 were 2.38 min (Figure 1a and b) . Similarly, retention times for sitagliptin and Sitagliptin D4 were 1.37 and 1.38 min, respectively (Figure 2a and b) . As per the FDA guidelines, standards should be preferably identical to the analyte (19) and hence deuterated standards were used as the reference compounds. No interfering peaks were observed in the blank at the retention times corresponding to both analytes and IS, indicating that the procedure is specific to metformin as well as to sitagliptin.
Linearity of the calibration plot Calibration plots of metformin and sitagliptin showed that the calibrations were linear in the concentration ranges of 10-2,206 ng/mL and 3-800.5 ng/mL, respectively. Residual sum of squares were obtained to check the large linear ranges used for both drugs. Limit of detection was found to be 2.5 ng/mL for metformin, whereas for sitagliptin it was 0.75 ng/mL. The signal-to-noise ratio was .3.0. The concentration of unknown is calculated from the equation y ¼ mx þ c using regression analysis of spiked plasma calibration standards with reciprocal of the square of the drug concentration (1/X 2 ).
Precision and accuracy
Intra-or interday precision and accuracy were determined by six replicate analysis of lower limit of quantification (LLOQC), LQC (within 3Â the LLOQC), middle QC (MQC) and HQC (one near the upper boundary of the standard curve) samples. Intraday precisions were ranged from 1.7 to 2.9% for metformin, whereas for sitagliptin those were ranged from 2.7 to 4.3% (Table III) . However, for LLOQC of Sitagliptin, the range was from 4.3 to 16.9%. Similarly, for interday batch, precision ranged from 2.2 to 4.1% for metformin and 3.7 to 13.1% for sitagliptin, which were well within the accepted limit as the per FDA guidelines ( 20% at LLOQC and 15% for others). Mean accuracy for interday batch ranged from 99.5 to 103.9% for metformin. Similarly, for sitagliptin, the range was 95.5 -103.6% (Table III) .
Recovery
The percentage recovery was determined by comparing the mean peak area of analyte obtained by injecting six extracted samples of LQC, MQC and HQC with the mean peak area obtained by injecting respective aqueous standard solutions. Mean percentage recovery was 92.1 with mean % CV of 2.9 for metformin. For sitagliptin, it was 104.5 and mean % CV was 3.5 (Tables IV and V) .
Stability: short-term/bench-top stability
To check whether the sample is stable during analysis, six aliquots of LQC and HQC samples were thawed and kept at room temperature (258C) for 9 h, which has been decided based on the time required for analysis. The samples were then processed and analyzed as mentioned above. No significant differences were noticed when these results were compared with those obtained from freshly spiked samples, indicating that both metformin and sitagliptin were stable at room temperature (Tables VI  and VII) .
Autosampler stability
The stability of the processed samples in the autosampler during analysis was determined by using six aliquots of LQC and HQC samples. The stabilities of metformin and sitagliptin were assessed for 20 h, the expected run time for batches of validation samples. The result was then compared with that obtained from fresh QC samples. For IS in-injector stability, the IS/analyte area ratio of MQC stored in an autosampler for 20 h was compared against freshly prepared MQC samples. No significant difference in the results indicated that the analytes and IS are stable for at least 20 h in the autosampler (Tables VI and VII) .
Freeze -thaw stability Analyte stability was determined after four freeze -thaw cycles for six aliquots of each of the LQC and HQC. The samples were stored below 2708C for 24 h and then allowed to thaw at room temperature. After complete thawing, the samples were again stored at same temperature (2708C) for 12 h. The freeze -thaw cycle was repeated another three times before analyzing the samples. No differences were noted when the results were compared with the fresh QC samples. It does indicated that both metformin and sitagliptin in K 2 EDTA human plasma for four freeze-thaw cycles (Tables VI and VII) .
Wet extract stability
To check whether the sample is stable after processing, six aliquots of LQC and HQC samples were processed and kept at room temperature for 7 h. The samples were then analyzed as mentioned above. No significant differences were noted when these results were compared with those obtained from the fresh QC samples, indicating that processed samples of metformin and sitagliptin were stable at room temperature (Tables VI  and VII) .
Short-/long-term stock solution stability
To ensure that analyte is stable in appropriate solution for a short period of time at room temperature, the stabilities of stock and working solutions of metformin and sitagliptin were evaluated at room temperature for 47 h. There were no significant changes in stabilities of the stock and working solutions on keeping at room temperature for 47 h (Table VIII) . Similarly, to ensure that analytes are stable during storage condition, the stock solutions of both metformin and sitagliptin were kept for 45 days in the refrigerator (2-88C) and then analyzed. Table VIII indicates that both analytes were stable during this period.
Bioequivalence study
Having demonstrated that the method was accurate and precise within the defined acceptance criteria, the assay was applied to a pharmacokinetic study to compare the bioequivalence of a 'test' product to that of 'marketed' product among healthy volunteers in India. The study was conducted as per the regulations and prior approval for the study was obtained from an independent ethics committee. The pharmacokinetic parameters derived from the analysis are listed in Tables IX and X. The ratio and 90% confidence interval for the log-transformed pharmacokinetic parameters AUC 02t , AUC 021 and C max fell within 80.00 -125.00% for metformin and sitagliptin. Hence, the test product of extended-release tablet containing both metformin (1000 mg) and sitagliptin (100 mg) can be considered as bioequivalent to the reference product under fasting condition. The data generated by LC -MS-MS have therefore been successfully used to assess the pharmacokinetic/pharmacodynamic relationship of potential drug candidates in relation to metformin/sitagliptin.
Discussion
Liquid chromatography coupled with atmospheric pressure ionization tandem mass spectrometry is presently widely used for the quantitative determination of drugs in biological matrices. There are several advantages of this technique including high specificity, sensitivity and throughput. However, co-eluting matrix components, which are not observed in the chromatogram, can have a detrimental effect on the analysis, since they can cause ion suppression or enhancement of the analyte. It is difficult to set chromatographic conditions that produced sharp peak shape and adequate response for analytes with widely different physicochemical properties. However, the separation and elution of all four compounds (both analytes and ISs) in a very short time were achieved by LC -MS-MS using a short reverse phase column and ESI as the ionization source (19) . But, simultaneous determination of metformin and sitagliptin on a single chromatographic run on a reverse phase column and ESI as an ionization source is a risk due to ion suppression from endogenous material in the sample matrix and variable recovery (18) . This problem has, however, been overcome in the present method by the use of an ion exchange column which reduces the risk of ion suppression by selective binding due to ionic interaction and also by using a fundamentally different ionization mechanism, API. Even sensitivity of this method is better than earlier reported ones. Lower limits of concentration range in linear calibration curves (10 ng/mL for metformin and 3 ng/mL for sitagliptin, respectively) were lower than the earlier reported ones (13, 18 -20) . Limits of detection were found to be even lower (2.5 ng/mL for metformin and 0.75 ng/mL for sitagliptin), with a signal-to-noise ratio of .3.0.
It is also a challenge to extract simultaneously a highly polar compound (metformin) and a less polar compound (sitagliptin) from plasma. By using a simple protein precipitation technique with acetonitrile, we consistently achieved . 90% recovery for both metformin and sitagliptin, compared with 40.5 and 64.5% reported by Bonde et al. (19) .
Matrix factors for both metformin and sitagliptin were evaluated as the ratio of area response in the presence and absence of matrix. % CV ( 15%) for both analytes indicates the absence of any matrix effect. Moreover, no endogenous interferences were detected at the retention time of selected drugs and IS during analyses of eight blank plasma. Therefore, the developed method is selective and specific. The acceptable limit for both intra-and interday accuracy and precision is +15% of the nominal values for all, except for LLOQC which should be within +20%. In this method, both intra-and interday accuracy and precision are well within this limit, indicating that the developed method is precise and accurate for both metformin and sitagliptin. Moreover, the method is very sensitive as it can detect and estimate the drugs at very low level which is most often encountered during bioanalysis.
Conclusion
A simple, accurate, precise, sensitive and reproducible LC -MS-MS method developed and validated for the simultaneous determination of metformin and sitagliptin in human plasma has been reported. The sample extraction procedure described here is a simple precipitation method which, however, produces cleaner samples with a relatively less matrix effect and also with a better percentage recovery. Moreover, the use of atmospheric pressure ionization technique along with an SCX column further reduces the matrix effect drastically. The method was applied successfully to quantify metformin and sitagliptin in the pharmacokinetic study. The assay was validated in terms of accuracy and precision for use in a pharmaceutical discovery environment, and the analysis of real pharmacokinetic study samples was demonstrated. This technique could potentially be applied to therapeutic drug monitoring also. 
